Congress must protect the research behind tomorrow’s cures

Here's the reality: when it comes to cutting-edge medicine, "Made in America" isn't just a patriotic slogan—it's a strategic imperative. Former Rep. Mimi Walters' call to prioritize domestic biomedical research and tighten regulatory reins isn't fear-mongering; it's a sobering look at supply chains that are both biological and geopolitical. The pandemic proved we cannot afford to be dependent on foreign labs for our health security. The pitch for stricter oversight walks a tightrope. On one hand, Americans expect the FDA to be a gatekeeper, not a rubber stamp. On the other, suffocating red tape could chase the next breakthrough to Shanghai or Basel. Walters is correctly signaling that the future of cures is a national security issue—connecting directly to the broader decoupling debate. Just as we fight for chip dominance, we now must fight for biotech sovereignty. The stakes are literally life-saving. But let's not overcorrect into a fortress mentality. The goal isn't isolation; it's resilience. Fund domestic labs, streamline approvals for safe breakthroughs, and create an environment where innovation thrives without sacrificing oversight. If Washington threads that needle, we lead. If not, the only prescription for American medical independence will be a bitter one. Remember: